Document is current
Any future updates will be listed below
-
Authors
Ford, Jodi https://orcid.org/0000-0002-0778-4667
Slesnick, Natasha https://orcid.org/0000-0002-6629-0333
Browning, Christopher https://orcid.org/0000-0001-7807-3849
Feng, Xin https://orcid.org/0000-0003-4046-5374
Yilmazer, Tansel https://orcid.org/0000-0002-8143-3427
Boettner, Bethany https://orcid.org/0000-0002-4390-9447
Luthy, Jacsen https://orcid.org/0009-0009-4784-7384
Fitzpatrick, Margaret https://orcid.org/0000-0002-9773-454X
Pinkus, Lia https://orcid.org/0000-0002-4787-4915
Holowacz, Eugene https://orcid.org/0000-0002-2409-1045
Hang, Celina
-
Funding
Funding for this research was provided by:
National Institute of Drug Abuse (1R01DA059411)
- License Information
-
More Information
Article History
Received: 19 December 2025
Accepted: 11 June 2026
First Online: 15 July 2026
Declarations
Ethics approval and consent to participate: The study was reviewed and approved by The Ohio State University Biomedical Sciences Institutional Review Board [2023H0244] in accordance with the Declaration of Helsinki. Written informed consent/assent is obtained from all research participants.
Consent for publication: Not applicable.
Dissemination plans: The trial is detailed in ClinicalTrials.gov. Study findings will be presented at national and/or international conferences and local, community outlets. All final peer-reviewed manuscripts will be submitted as open-access to the digital archive, PubMed Central, and findings of the trial will be summarized and posted on ClinicalTrials.gov and the lab’s website to enhance public accessibility.
Competing interests: The authors declare no competing interests.
